ABT vs ONC
Abbott Laboratories (ABT) and BeOne Medicines Ltd. (ONC) are both filed with the SEC under Pharmaceutical Preparations. ONC is 2.8× ABT's size by market cap ($550.6B against $194.4B); ONC trades at the higher fiscal-year P/E (1960.5× against 30.0×); ABT reports the higher net margin (14.7% against 5.4%); ONC grew sales faster over three years (+55.7% against +0.5%); and over the past year ONC returned +23.1% against ABT's -13.0%.
| ABT | ONC | |
|---|---|---|
| Last close | $112.47 | $366.73 |
| Market cap | $194.4B | $550.6B |
| P/E (FY) | 30.0× | 1960.5× |
| P/S | 4.4× | 103.0× |
| EV/EBITDA | — | 929.1× |
| Gross margin | — | 87.5% |
| Operating margin | 18.2% | 8.4% |
| Net margin | 14.7% | 5.4% |
| Return on equity | 13.1% | 7.5% |
| Sales growth (3y) | +0.5% | +55.7% |
| EPS growth (3y) | -1.6% | — |
| Dividend yield | 2.1% | — |
| 1-year return | -13.0% | +23.1% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| ABT | ONC | |
|---|---|---|
| Institutional holders (13F) | 3,066 | 280 |
| Insider buyers − sellers (180d) | -3 | -5 |
| Congressional trades disclosed (180d) | 14 | 0 |
| Executive-branch officials on file — trades disclosed (180d) | 17 | 0 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
ABT vs ONC: common questions
- Is ABT bigger than ONC?
- ONC carries the larger market cap — $550.6B against $194.4B, both struck on 2026-08-27.
- Which trades at a higher P/E, ABT or ONC?
- ONC, at a fiscal-year 1960.5× against 30.0× for ABT. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have ABT and ONC performed over the past year?
- ONC returned +23.1% and ABT -13.0%, measured on the trailing calendar year to the last close.
- How many institutions hold ABT and ONC?
- 3,066 13F filers report a position in ABT and 280 in ONC, on the latest quarter in the panel.
- Are ABT and ONC in the same industry?
- Both are filed with the SEC under Pharmaceutical Preparations, which is the classification this pairing is built on.
ABT overview → · ONC overview → · ABT institutional ownership → · ONC institutional ownership → · Congress and ABT → · Executive branch and ABT →
More in Pharmaceutical Preparations: ABBV vs ABT · ABBV vs ONC · ABBV vs REGN · ABBV vs TEVA
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/abt-vs-onc